- Home
- SPRO vs LITM Comparison
SPRO vs LITM Comparison
Compare SPRO & LITM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- LITM
- Stock Information
- Founded
- SPRO 2013
- LITM 2018
- Country
- SPRO United States
- LITM Canada
- Employees
- SPRO N/A
- LITM N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- LITM Other Metals and Minerals
- Sector
- SPRO Health Care
- LITM Basic Materials
- Exchange
- SPRO Nasdaq
- LITM Nasdaq
- Market Cap
- SPRO 45.7M
- LITM 50.3M
- IPO Year
- SPRO 2017
- LITM 2021
- Fundamental
- Price
- SPRO $0.72
- LITM $0.51
- Analyst Decision
- SPRO Buy
- LITM
- Analyst Count
- SPRO 4
- LITM 0
- Target Price
- SPRO $5.00
- LITM N/A
- AVG Volume (30 Days)
- SPRO 118.7K
- LITM 19.8M
- Earning Date
- SPRO 03-27-2025
- LITM 04-08-2025
- Dividend Yield
- SPRO N/A
- LITM N/A
- EPS Growth
- SPRO N/A
- LITM N/A
- EPS
- SPRO N/A
- LITM N/A
- Revenue
- SPRO $47,977,000.00
- LITM N/A
- Revenue This Year
- SPRO N/A
- LITM N/A
- Revenue Next Year
- SPRO N/A
- LITM N/A
- P/E Ratio
- SPRO N/A
- LITM N/A
- Revenue Growth
- SPRO N/A
- LITM N/A
- 52 Week Low
- SPRO $0.70
- LITM $0.15
- 52 Week High
- SPRO $1.81
- LITM $1.88
- Technical
- Relative Strength Index (RSI)
- SPRO 38.19
- LITM 47.18
- Support Level
- SPRO $0.75
- LITM $0.54
- Resistance Level
- SPRO $0.80
- LITM $0.64
- Average True Range (ATR)
- SPRO 0.05
- LITM 0.09
- MACD
- SPRO 0.00
- LITM 0.01
- Stochastic Oscillator
- SPRO 9.09
- LITM 38.73
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About LITM Snow Lake Resources Ltd.
Snow Lake Resources Ltd is a Canadian clean energy exploration company with a world-wide portfolio of clean energy mineral projects comprised of two uranium projects and two hard rock lithium projects. Its Projects include: The Black Lake Uranium Project, the Engo Valley Uranium Project, The Shatford Lake Project, and the Snow Lake Lithium Project.